Real world evidence demonstrates the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients

• An independent real-world study, performed at Hannover Medical School, has found that 85% of tinnitus patients experienced a reduction in their tinnitus symptoms
• This study showed that six to twelve weeks of treatment using Lenire, can safely achieve clinically meaningful improvements in tinnitus symptom severity in a real world clinical setting
• The real world data are consistent with the outcomes of a large-scale clinical trial which included 326 participants and 86.2% of treatment-compliant participants reported an improvement in their tinnitus symptoms after a twelve week period using Lenire. When followed up twelve months post treatment, 80.1% of treatment-compliant participants had sustained improvements in their tinnitus symptoms
• The TENT-A1 study represents one of the largest and longest followed-up clinical trials ever conducted in the tinnitus field

Click here to learn more.

About SVMPharma

SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.

About DISTILL

DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

Ref: RWEMAR2022HBA